RANI
Rani Therapeutics Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.87
+1.54%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.9M | 1.6M | 1.0M | — | — |
| Cost of Revenue | 161.0K | 900.0K | — | 822.0K | — |
| Gross Profit | 4.7M | 733.0K | 1.0M | (822.0K) | — |
| Operating Expenses | |||||
| R&D Expense | 18.3M | 20.2M | 26.7M | 39.6M | 36.6M |
| SG&A Expense | 19.5M | 19.7M | 23.9M | 26.5M | 26.8M |
| General & Admin Expense | 19.5M | 19.7M | 23.9M | 26.5M | 26.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (161.0K) | (900.0K) | 3.7M | (822.0K) | — |
| Total Operating Expenses | 37.7M | 39.0M | 54.3M | 65.3M | 63.5M |
| Cost and Expenses | 37.8M | 39.9M | 54.3M | 66.1M | 63.5M |
| Operating Income (EBIT) | (33.0M) | (38.3M) | (53.3M) | (66.1M) | (63.5M) |
| Non-Operating | |||||
| Interest Income | 1.3M | 827.0K | 1.8M | 3.3M | 1.2M |
| Interest Expense | 1.2M | 2.9M | 5.0M | 5.1M | 1.1M |
| Net Interest Income | 111.0K | (2.1M) | (3.3M) | (1.8M) | 177.0K |
| Other Non-Op Income/Expense | (465.0K) | (2.6M) | 23.3M | (1.8M) | 177.0K |
| Non-Operating Income (excl Interest) | (288.0K) | (251.0K) | (1.8M) | (3.3M) | (1.2M) |
| EBT (Pre-Tax Income) | (33.4M) | (41.0M) | (30.0M) | (67.9M) | (63.3M) |
| Income Tax Expense | — | — | 26.6M | — | 70.0K |
| Bottom Line | |||||
| Net Income | (30.1M) | (29.7M) | (30.0M) | (34.0M) | (30.6M) |
| Earnings from Cont. Ops | (33.4M) | (41.0M) | (56.6M) | (67.9M) | (63.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (30.1M) | (29.7M) | (30.0M) | (34.0M) | (30.6M) |
| Per Share | |||||
| Basic EPS | ($0.27) | ($0.45) | ($1.05) | ($1.33) | ($1.28) |
| Diluted EPS | ($0.27) | ($0.45) | ($1.05) | ($1.33) | ($1.28) |
| Revenue Per Share | $0.03 | $0.02 | $0.04 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 187.2M | 66.1M | 28.5M | 25.5M | 23.8M |
| Diluted Shares Outstanding | 187.2M | 66.1M | 28.5M | 25.5M | 23.8M |
| Profitability Metrics | |||||
| EBITDA | (32.1M) | (37.2M) | (50.5M) | (62.0M) | (61.7M) |
| D&A | 570.0K | 900.0K | 1.0M | 822.0K | 548.0K |
| EBIT | (32.7M) | (38.1M) | (51.6M) | (62.8M) | (62.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026